New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
Sep 18, 2024 East Hanover, September 18, 2024 – Novartis today announced new data from the ALITHIOS open-label extension study. Data…
Press Release: FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a…
Stuart Schlossman
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
September 2, 2024 • In the HERCULES study, tolebrutinib met the primary endpoint in delaying time to onset of confirmed…
Stuart Schlossman
Why BOTHER taking MS Medications?
No excerpt…
Stuart Schlossman
“MS101, The Basics” with Aaron Boster, MD
At the 2024 MS WELLNESS SUMMIT, Doctor Aaron Boster, MD an MS Neurologist, discusses his 6-for-6 for YOUR care in…
Stuart Schlossman
Prescription Assistance
If you need help paying for your medication, our guide can help you find the right assistance. This guide was…
Stuart Schlossman
Different lymphocyte counts of ms patients treated with ofatumumab and ocrelizumab
Christoph Friedli 1 2, Nik Krajnc 3 4, Helly N Hammer 1, Stefanie Marti 1, Tobias Zrzavy 3 4, Maria E Evangelopoulos 5, Ioanna Kapsali 5, Paulus Rommer 3 4, Thomas Berger 3 4, Andrew Chan 1, Gabriel Bsteh 3 4, Robert Hoepner 1 Affiliations expand Abstract Introduction: Patients with Multiple…
Stuart Schlossman
Breaking news: Committee favors approval of under-the-skin Ocrevus in Europe
By: Andrea Lobo, PhD — Written – April 30, 2024 New formulation recommended by CHMP would be faster, easier for…
Stuart Schlossman
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)
April 17, 2024 Download PDF New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis…
Stuart Schlossman
Press Release: TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Apr 18, 2024 PDF Version NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), announced that…
Stuart Schlossman
